Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
November 12, 2021 08:00 ET | Vir Biotechnology, Inc.
– New data from ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate notable reductions in HBsAg and support their positive safety profiles – SAN FRANCISCO, Nov. 12, 2021 ...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
October 15, 2021 08:30 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health...
Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®
October 20, 2017 07:30 ET | Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine...
Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
October 05, 2015 16:05 ET | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...